---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-24-000039"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T14:02:59.170500+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zymeworks Q2 2024 net loss $69.3M; cash $395.9M; zanidatamab BLA priority review by Nov 29

## Summary
- Net loss for H1 2024: $69.3M vs $75.5M loss in H1 2023; revenue $29.3M (down from $42.6M).
- Cash, equivalents and marketable securities $395.9M as of June 30, 2024; runway into 2H 2027.
- FDA granted Priority Review for zanidatamab BLA in 2L HER2+ BTC; PDUFA date Nov 29, 2024.
- Discontinued zanidatamab zovodotin (ZW49) to focus on ZW171 and ZW191 Phase 1 starts in 2H 2024.
- Appointed Leone Patterson as EVP, Chief Business Officer and CFO, effective Sep 1, 2024.

## SEC filing metadata
- accession: 0001937653-24-000039
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000039/0001937653-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765324000039/zyme-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-24-000039
- JSON: https://secwatch.observer/filing/0001937653-24-000039.json
- Plain text: https://secwatch.observer/filing/0001937653-24-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.